**About the Editor**

## **Anica Dricu**

In 1997, Anica Dricu obtained a PhD in Experimental Pathology at the Karolinska Institutet in Stockholm. She then joined its Oncology Pathology Department, becoming Docent in Experimental Oncology in 2006, at the same Medical University, Karolinska Institutet. From 2009, she has been a professor at the University of Medicine and Pharmacy of Craiova.

Her current research addresses the role of growth factor receptors (GFRs) in the diagnosis and therapy of solid tumours. The dysregulation of GFR signaling in malignant diseases makes these membrane receptors important diagnostic, predictive and prognostic biomarkers. Targeted therapy, also called precision medicine or personalized medicine, also involves GFRs. She focuses particularly on small molecule cancer drugs, used to target GFR activation and downstream signaling. These drugs have a significant impact on the modern modality in treating cancers.

She has published several articles, and she serves as a member of several editorial and review boards for peer-reviewed journals.
